← Leaderboards
Alfonso Bellacosa
Fox Chase Cancer Center
$4,925,339
Attributed
$5,232,370
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $383.4K · FY2005–22$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$5,232,370 · 5
By mechanism
R01$3,657,389 · 1
R21$769,145 · 2
R29$618,836 · 1
R03$187,000 · 1
Top collaborators
- Timothy Yen4 shared
Others in their field
Top investigators on “Dna Repair”
- John A Tainer · Scripps Research Institute$45,990,082
- Aziz Sancar · University Of North Carolina Chapel Hill$30,640,499
- Patrick Sung · University Of Texas Hlth Sci Ctr San Ant$30,442,761
- John M Essigmann · Massachusetts Institute Of Technology$27,654,594
- Loic Le Marchand · University Of Hawaii At Manoa$26,643,180
- Maria Jasin · Sloan-Kettering Institute For Cancer Res$25,953,946
Research focus
Dna RepairCell LineCytosineRepair EnzymeTumorSiteMalignant NeoplasmsIn VitroGene ExpressionNovel StrategiesDna Repair EnzymesEpigenetic ProcessAffectEmbryoMismatch RepairDemethylationMutationFibroblastsDna MethylationGerm LinesIn VivoDeaminationEpigenomicsGenome
Grant awards (21)
Identification of first-in-class epigenetic inhibitors that target Thymine DNA Glycosylase (TDG) for future precision therapy of metastatic melanoma$93,500
R03 · FY2022 · CA · contact PI
Identification of first-in-class epigenetic inhibitors that target Thymine DNA Glycosylase (TDG) for future precision therapy of metastatic melanoma$93,500
R03 · FY2021 · CA · contact PI
TDG as a novel target to enhance gemcitabine killing of pancreatic cancer cells$194,119
R21 · FY2016 · CA · contact PI
TDG as a novel target to enhance gemcitabine killing of pancreatic cancer cells$232,943
R21 · FY2015 · CA · contact PI
Regulation of Genomic and Epigenomic Stability at CpG Sites$369,057
R01 · FY2014 · CA · contact PI
Regulation of Genomic and Epigenomic Stability at CpG Sites$357,643
R01 · FY2013 · CA · contact PI
Regulation of Genomic and Epigenomic Stability at CpG Sites$380,116
R01 · FY2012 · CA · contact PI
Regulation of Genomic and Epigenomic Stability at CpG Sites$371,945
R01 · FY2011 · CA · contact PI
Regulation of Genomic and Epigenomic Stability at CpG Sites$383,448
R01 · FY2010 · CA · contact PI
The MED1 Protein in DNA Damage Response and Repair$357,262
R01 · FY2008 · CA · contact PI
The MED1 Protein in DNA Damage Response and Repair$357,358
R01 · FY2007 · CA · contact PI
The MED1 Protein in DNA Damage Response and Repair$368,125
R01 · FY2006 · CA · contact PI
The MED1 Protein in DNA Damage Response and Repair$355,212
R01 · FY2005 · CA
The MED1 Protein in DNA Damage Response and Repair$357,223
R01 · FY2004 · CA
NEW HUMAN DNA REPAIR ENDONUCLEASE$207,619
R29 · FY2002 · CA
MED1 MUTATIONS IN COLORECTAL CANCER$169,666
R21 · FY2002 · CA
MED1 MUTATIONS IN COLORECTAL CANCER$172,417
R21 · FY2001 · CA
NEW HUMAN DNA REPAIR ENDONUCLEASE$121,377
R29 · FY2001 · CA
NEW HUMAN DNA REPAIR ENDONUCLEASE$85,496
R29 · FY2001 · CA
NEW HUMAN DNA REPAIR ENDONUCLEASE$117,844
R29 · FY2000 · CA
NEW HUMAN DNA REPAIR ENDONUCLEASE$86,500
R29 · FY2000 · CA